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Rhabdomyolysis and acute encephalopathy in late 
onset medium chain acyl-CoA dehydrogenase 
deficiency
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Abstract
A previously asymptomatic 30 year old 
man presented with rhabdomyolysis, 
muscle weakness, and acute encephalo­
pathy after strenuous exertion in the cold 
without adequate food intake. Serum and 
muscle carnitine concentrations were 
decreased. Urinary excretion of carnitine 
and glycine esters and biochemical 
examination of skeletal muscle and 
fibroblasts led to the diagnosis of medium 
chain acyl-CoA dehydrogenase (MCAD) 
deficiency. A point mutation at 
nucleotide position 985 of the coding 
region of the MCAD gene was found. The 
MCAD protein was synthesised in the 
patient’s fibroblasts at a normal rate, but 
was unstable. In general, patients in 
whom the 985 point mutation has been 
established show much more severe clini­
cal symptoms and other symptoms than 
those seen in this patient. The relation of 
the 985 point mutation and the residual 
MCAD activity to the symptoms is not as 
straightforward as previously thought.
(J  Neurol Afeurosurg Psychiatry 1995^58:209-214)
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Rhabdomyolysis (acute muscle necrosis) can 
be due to various acquired or hereditary 
causes.12 The hereditary causes include spe­
cific defects of metabolism—for example, 
enzyme defects in glycogen catabolism and 
glycolysis. ^ Of the disorders of muscle lipid 
metabolism, carnitine palmitoyltransferase 
deficiency is one of the most common meta­
bolic causes of rhabdomyolysis/1 Recurrent 
attacks of rhabdomyolysis have been found in 
three patients reported to have myopathic car­
nitine deficiency.5-7 Recently a few other 
defects of fatty acid oxidation have been asso­
ciated with rhabdomyolysis.H“10
Medium chain acyl-CoA dehydrogenase 
(MCAD) deficiency is thought to be the most 
common disorder of fatty acid oxidation.11 11 
As an inborn error of metabolism it has been 
recognised with increasing frequency in chil­
dren with a Reye-like syndrome. As a conse­
quence of the disturbance in fatty acid 
oxidation, MCAD deficiency is associated 
with acute attacks of hypoketotic hypogly- 
caemia and Cfi-Ci<} dicarboxylic aciduria. The 
attacks are provoked by stress, fever, viral 
illness, and fasting. Some patients, earlier
classified as having carnitine deficiency, later 
seemed to have MCAD deficiency.13 In urine 
a characteristic profile of C6-Ci(> acylcarnitines 
can usually be shown, as well as acylglycines 
(for example, suberylglycine). The presence 
of octanoylcarnitine in plasma may be a 
specific indication for MCAD deficiency.15
The age of initial presentation of MCAD 
deficiency varies widely. Most patients pre­
sent acutely, usually between infancy and the 
second year of life. Duran et al described an 
asymptomatic adult man,16
Recent DNA studies have shown a high 
prevalence of a point mutation at nucleotide 
position 985 of the coding region of the 
MCAD gene in patients deficient in MCAD.17
Here we describe the first patient with an 
initial clinical presentation of rhabdomyolysis 
and acute encephalopathy in adult life, who 
was later proved to have MCAD deficiency, 
established both at the enzyme and DNA 
level.
Case history
A 30 year old man developed progressive 
muscle weakness in his arms and legs after a 
day of strenuous exercise in the cold without 
taking any food. He complained of headache 
and nausea, began vomiting, and produced 
dark brown coloured urine. At the end of the 
day he became lethargic, irritable, and agi­
tated. He was admitted with lowered con­
sciousness. He had had another episode of 
vomiting, headache, and motor restlessness 
one year before. This occurred during a long 
motorbike trip during which he did not eat. It 
was said that he sometimes had an acetone­
like breath, especially when he had not eaten. 
The family history was non-contributory.
On admission the patient was delirious. 
Blood pressure, pulse rate, and temperature 
were normal. Due to generalised muscle 
weakness, he was unable to stand upright. 
Muscle stretch reflexes were normal and sym­
metric. His liver was not enlarged. There was 
no focal neurological deficit. On admission 
creatine kinase activity in serum was 4000 
IU/1 (normal range 15-91 IU/1) and myoglo­
bin was 134 /¿g/1 (normal < 85 f.igi\). The cal­
cium concentration of 2-20 mmol/1 was low 
normal (normal range 2*20~2’60). Phosphate 
concentrations were increased to 1*70 mmol/1 
(normal range 0*76-1‘24). Blood glucose was 
normal. Activity of transaminases in serum 
was raised, whereas y-glutamyltransferase 
activity was normal. Potassium concentration 
was increased to 5-8 mmol/1 (normal range
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3*3-4-4 mmol/1). The patient had a low uri­
nary output for two days (500 ml per 24 
hours). A transient increase of plasma urea to 
26 mmol/1 (normal range 3' 1-7 *5 mmol/1) and 
creatinine to 193//mol/l (normal range 
70-106 /¿mo 1/1) indicated a moderate renal 
insufficiency. The protein and ketone body 
reaction in urine was slightly positive.
Protein in CSF was slightly increased (530 
mg/1; normal value for age 150-450 mg/1), as 
was lactate (1690 /¿mol/1; normal range 
1200-1600 /¿mol/1). The concentration of glu­
cose was normal. There was no clinical or lab­
oratory evidence for endocrinological 
immunological3 and chronic infectious dis­
eases, vitamin deficiency, or disorders caused 
by toxic agents.
Electroencephalography showed a gener­
alised slowing background pattern consistent 
with encephalopathy. During the acute phase 
cerebral CT showed thin lateral ventricles 
indicative of cerebral oedema. Electro­
myography showed normal results. Electro­
cardiography showed signs of left ventricle 
hypertrophy and repolarisation disturbances. 
Two years later the results of EEG, cerebral 
CT, and ECG were normal.
Diagnostic investigations
CLINICAL CHEMICAL ASPECTS
After the patient had made a complete 
recovery, biochemical studies were performed 
to determine the aetiology of the rhabdomyol- 
ysis. The activity of carnitine palmitoyltrans­
ferase I and II in leucocytes was normal. 
Serial measurements of carnitine in serum18 
showed a concentration of non-esterified car­
nitine in serum fluctuating between 6 and 38 
jiimoVl (table) with a mean level of 21 //mo 1/1 
(controls > 20 (mean 38 /tmol/1)), Organic 
acids were determined in urine by gas chro­
matography-mass spectrometry. Fast atom 
bombardment mass spectrometry was used to 
analyse the excretion profile of acylcar- 
nitines.19 There was a moderate dicarboxylic 
aciduria with increased excretion of suberyl- 
glycine, with an increase in excretion on pro­
longed fasting. The acylcarnitine analysis 
showed increased excretion of almost exclu­
sively octanoylcarnitine. The identity of these 
acylcarnitines was confirmed by accurate 
mass measurements and by linked scanning of 
the isobutyl esters.
Normal concentrations of amino acids were 
found in serum and urine.
Seram and muscle carnitine concentrations before and 
during carnitine treatment in the patient and controls
Patient 
— Carnitine 4- Carnitine
Controls
Serum (//mol/I): 
Total carnitine 13-43 25-78 >25
Non-esterified carnitine 6-38 13-41 >20
Muscle (/¿mol/g wet weight): 
Total carnitine 0*84 0-97
•
2-7-4-6
Non-esterified carnitine 0-73 0-61 2 *2-4-2
MORPHOLOGICAL STUDIES
A biopsy from the vastus medialis muscle was 
taken one month after the rhabdomyolytic 
period. Only 20% of the fibres were type I 
(normal 35-50%). In semithin toluidine 
stained Epon sections there was an increased 
amount of lipid droplets between the myofib­
rils, mainly in type I fibres. Electron 
microscopy showed numerous lipid droplets 
as well as local glycogen accumulation. 
Morphometric studies20 showed that the vol­
ume density of lipid droplets (Vn): volume 
density of the myofibrils (Vmf) ratio was twice 
the control mean (Vi/Vmf patient 0-87 (SEM 
0-15), controls 0-36 (SEM 0-07)).
BIOCHEMICAL ASPECTS
Concentrations of total and non-esterified 
carnitine in muscle tissue18 were about 25% of 
control values (table). The activities of carni­
tine palmitoyltransferase I and II, citrate syn­
thase, creatine kinase, cytochrome c oxidase, 
palmitoyl-CoA synthetase, and succinate 
dehydrogenase were normal in skeletal mus­
cle.21
The oxidation rates of radiolabelled palmi- 
tate, octanoate, butyrate, and pyruvate by 
intact cultured fibroblasts were determined 
according to Veerkamp et ah22 The rate of 
octanoate was diminished to 5% of the 
control mean (0*11 v 2-4 (SD 0-9)) nmoLh"1. 
mg-1 protein. MCAD deficiency was estab­
lished in fibroblast homogenate (1*6 v 15*6 
(6-2) mU.U 1 citrate synthase), using an elec­
tron transfer fiavoprotein linked assay.23 The 
activities of short chain and long chain acyl- 
CoA dehydrogenases were normal. In a 600 g 
supernatant of a frozen skeletal muscle speci­
men, with phenazine methosulphate and 
dichlorophenolindophenol as electron 
acceptor,24 MCAD activity was not above the 
detection limit.
MOLECULAR BIOLOGICAL ASPECTS
Genomic DNA studies were performed on 
muscle tissue and skin fibroblasts. The DNA 
was extracted from cultured skin fibroblasts 
and skeletal muscle homogenate; 2 /¿g was 
used to amplify an 87 bp region using the 
polymerase chain reaction (PCR). The 
oligonucleotide primers used create a restric­
tion site for Ncol in the mutant fragment.25 
After an initial eight minute denaturation step 
at 94°C, the PCR reaction was repeated for 
30 cycles (one minute denaturation at 94° C; 
two minutes annealing at 50°C; and three 
minutes extension at 72°C; the final extension 
was for eight minutes). The 87 bp PCR prod­
uct was precipitated and resuspended in 20 ¡A 
of H20. A 10 pi\ aliquot was digested with 5U 
of Ncol at 37°C for two hours. The original 
PCR fragment and the products of the restric­
tion digest were treated by electrophoresis on a 
3% agarose gel containing ethidium bromide.
Digestion with Ncol of the amplified DNA 
from the patient's fibroblasts and muscle 
showed only 61 and 26 bp fragments and no 
87 bp fragment (fig 1, lanes 8 and 10). 
Therefore the patient was apparently homozy­
gous for the 985 point mutation.
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Figure 1 Electrophoretic pattern of the 87 bp fragments and their Ncol digestion products 
after PGR amplification of muscle and fibroblast DNA from patient and controls, The 61 
bp Ncol digestion product is distinct, the 26 bp product is hardly visible. Lanes 1-6 = 
control muscle; lanes 7-8 = patient’s fibroblasts; lanes 9-10 = patient’s muscle j odd 
numbers = original PGR fragments; even numbers = digested PCR products.
The synthesis and stability of the MCAD 
protein was estimated in cultured skin fibro- 
blasts. The normal medium for growing cells 
was Eagle’s minimum essential medium (E- 
MEM) supplemented with 10% fetal calf 
serum (FCS) and antibiotics. For 
[3 5 S] methionine incorporation experiments 
medium was removed from confluent mono­
layers. Each dish (area 65 cm2) was washed 
twice with phosphate buffered saline (PBS) 
and incubated at 37°C for two hours with 5 
ml labelling medium (E-MEM without 
methionine but with 10% FCS). This 
medium was replaced by 5 ml of fresh 
labelling medium containing L-PS]methion­
ine (100 jxd). After incubation for one hour 
at 37°C the medium was removed. In some 
experiments the degradation of the synthe­
sised protein was studied by incubating the 
cells for another six or 17 hours in normal 
medium with added unlabelled methionine. 
The cell layers were rinsed twice with PBS 
containing 2% unlabelled methionine and sol­
ubilised by the addition of 1 ml NETS 
medium (150 mM NaCl3 10 mM EDTA3 
0*5% Triton X-1005 0*25% sodium dodecyl- 
sulphate, and 2% unlabelled methionine, pH
1 2 3 4 5 6
Figure 2 Gel electrophoretic pattern of the M CAD  
protein synthesised in fibroblasts from patient and control. 
Lanes 1, 2 and 3 —patient; lanes 4} 5> and 6 = control; 
lanes 1 and 4 = MCAD protein synthesised in one hour; 
lanes 2 and 5 = MCAD protein synthesised in one hour, 
followed by six hours incubation in unlabelled medium; 
lanes 3 and 6 = MCAD protein synthesised in one hour3 
followed by 17 hours incubatioii in unlabelled medium.
7*4). The cell extract was centrifuged for one 
hour at 50 000 g. The supernatant was mixed 
with antiserum raised against pig liver 
M CAD/6 and incubated overnight at 4°C. 
The antigen-antibody complex was precipi­
tated by adding 100 /¿I of Staphylococcus 
aureus cell suspension^ followed by centrifuga­
tion (10 minutes at 1700 g). The pellet was 
washed four times with 2 ml of buffer contain­
ing 150 ml NaCl, 10 mM Tris-HCl, 1% 
Triton X-100, 1% deoxycholate, and 0-1% 
sodium dodecylsulphate, pH 7*2. The washed 
immunoprecipitate was solubilised by boiling 
(five minutes) in 50 /d of a denaturating 
buffer containing 8% mercaptoethanol and 
0*003% bromophenol blue. After 10 minutes 
centrifugation at 6000 g the supernatant was 
subjected to SDS-PAGE electrophoresis 
according to Laemmli,27 with 12% gels. The 
gels were treated for fluorography with Auto 
fluor (Amersham, Buckinghamshire, UK), 
dried, and fluorographed according to the 
supplier’s instructions.
Figure 2 shows the representative MCAD 
synthesis pattern. The MCAD protein was 
synthesised by the patient's fibroblasts at a 
normal rate (lane 1). The rapid disappearance 
of the protein incorporated radiolabelled 
methionine suggests a reduced stability of the 
protein (lanes 2 and 3). This is likely due to 
the impaired ability of the mutant 44 kDa 
monomers to form a stable tetramer.28^ 0
Carnitine treatment
The patient was treated with 8 g DL-carnitine 
daily for nine months. During the first month 
of carnitine supplementation the patient 
noticed an improvement in his general condi­
tion. Total carnitine concentrations in serum 
increased to near normal values and became 
more constant. The concentration of carnitine 
in muscle after nine months of carnitine treat­
ment had not increased (table), and lipid 
accumulation between the myofibrils had not 
disappeared. Supplementation was stopped as 
no objective improvement was seen.
Supplementation of 6 g/day riboflavin (the 
precursor of the flavin moiety of MCAD) had 
no beneficial effect.
Physiological tests
These tests were performed after informed 
consent of the patient.
FASTING STUDIES
Prolonged fasting studies were performed 
before the diagnosis of MCAD deficiency was 
established. The blood concentrations of the 
most important metabolites were determined 
before and after the patient had been treated 
with carnitine for 40 days. Figure 3 shows the 
results. The concentration of non-esterified 
fatty acids and ketone bodies increased during 
fastings whereas the ratio of ketone 
bodies:non-esterified fatty acids declined to 
0*33 at 48 hours without carnitine supple­
mentation. Glucose concentrations remained 
above 4*2 mmol/1 for 48 hours, but declined
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Figure 3 Concentrations 
of lactate3 ketone bodies> 
non-esterified (free) fatty 
acidsj and esterified and 
non-esterified carnitine in 
patient's blood during 
prolonged fasting. Left: 
without carnitine 
supplementation; Right: 
during carnitine 
supplementation (8  g D L- 
camitine).
o
c
oo
E3
<D
to
40
20
0
3200
_ o
Without
carnitine
2400
1600
800
0
0 12 24 36 48
Hours of fasting
Carnitine:
Free
Esterified
NEFAS
Lactate
Ketone
bodies
60
_  During
carnitine treatment
Hours of fasting
Carnitine:
Esterified
Free
NEFAS
Ketone
bodies
Lactate
at 55 hours to 3*0 mmol/1. A more pro­
nounced ketogenic response to fasting was 
found during carnitine treatment, whereas the 
non-esterified fatty acid concentration 
remained normal. The ketone bo dies: non- 
esterified fatty acids ratio was 0*68 after a 48 
hour fast. Glucose concentrations were 
maintained at 4-4 mmol/1. Apparently, the low 
carnitine concentrations had some patho­
physiological consequences besides the 
MCAD deficiency.
EXERCISE TESTS
The patient participated in two prolonged 
exercise tests31 (again before the diagnosis was 
made), one before and one during carnitine 
treatment. The patient became confused and 
experienced myalgia and nausea at the end of 
the exercise test without carnitine. The nor­
mal glucose concentration could no longer be 
maintained and lactate and ammonia concen­
trations showed a pronounced rise. During 
carnitine treatment he performed the pro­
longed exercise test with only slight myalgia 
and felt well after finishing. The glucose, lac­
tate, and ammonia concentrations did not 
become abnormal on this occasion.
Discussion
Since 1982 MCAD deficiency has been 
recognised in young children with episodic ill­
ness resembling Reye syndrome, provoked by 
viral illness, fever, and fasting.12 32-34 The first 
episode is often before the age of 2 years.1235 
The patients show a broad range of clinical 
presentation—namely, intolerance to fasting, 
episodic vomiting, lethargy, altered conscious­
ness, and even coma. The outcome may be 
severe and fatal, although complete recovery 
has also been described.16 Dependent on the 
degree of involvement of the liver, heart, and 
skeletal muscle, the clinical features may 
range from recurrent episodes of hypogly-
caemia to progressive muscle weakness and 
myalgia. Serum creatine kinase may be mod­
erately increased. In many patients the mus­
cular symptoms are not prominent, but some 
have symptoms of muscle weakness.
Techniques such as gas chromatography- 
mass spectrometry and fast atom bombard­
ment mass spectrometry make it possible to 
establish this metabolic disorder easily. 
Recently the value of measuring octanoylcar- 
nitine in plasma from patients suspected to 
have MCAD deficiency has been stressed.15 
Deficiency of MCAD has been associated 
with a molecular lesion involving an A to G 
nucleotide replacement at position 985 of the 
MCAD coding sequence,17 resulting in 
replacement of lysine329 by glutamic acid.30 
Although the prevalence of this mutation is 
high in patients deficient in MCAD, this 
approach is not yet appropriate to diagnose all 
patients with MCAD deficiency.30 37
Until now only one asymptomatic adult 
with MCAD deficiency has been described,16 
but his genotype was not established. We 
report the first patient with the MCAD point 
mutation at nucleotide position 985 whose 
clinical symptoms appeared at an adult age, 
whose medical history did not include muscle 
problems during childhood, and who did not 
have a positive family history. The clinical 
presentation of MCAD deficiency in this 
patient consisted of acute rhabdomyolysis and 
transient encephalopathy, provoked by pro­
longed exertion and fasting. Hitherto, rhab- 
domyolysis has not been associated with 
MCAD deficiency, although it has recently 
been described in several other defects of fatty 
acid oxidation.8-10 Fatty acids are important 
substrates for skeletal muscle, especially dur­
ing prolonged exercise and fasting. The 
decreased oxidative capacity of muscle tissue 
can result in a moderate accumulation of lipid 
droplets.
The transient encephalopathy in the pre-
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sent patient may be considered as a complica­
tion of rhabdomyolysis or a diminished supply 
of ketone bodies to the brain. The metabolism 
of the brain depends on glucose oxidation 
and, during fasting, on the oxidation of ketone 
bodies. Fatty acids are hardly metabolised by 
brain tissue. When the excess of medium 
chain fatty acids can no longer be metabolised 
by /^ -oxidation, as occurs in MCAD defi­
ciency, ketogenesis becomes impaired and co­
oxidation takes place. The impaired oxidation 
of octanoate may also have contributed to the 
development of encephalopathic symptoms. 
Octanoate disturbs the excretion of organic 
anionic compounds and mitochondrial func­
tioning, especially in the choroid plexus.38 It 
also induces epileptic and encephalopathic 
symptoms. Carnitine supplementation can 
stimulate detoxification of octanoate by esteri- 
fication, after which octanoylcarnitine is 
rapidly excreted.
The main dietary advice for patients with 
disorders of fatty acid oxidation is to have an 
adequate carbohydrate intake at regular 
times.14 The supplementation of this patient’s 
diet with carnitine may have improved exer­
cise tolerance and protected against the meta­
bolic consequences of prolonged fasting.
It is remarkable that in our patient, with the 
aberrant clinical symptoms, the same point 
mutation and the same biochemical features 
have been found as in the far more severe 
cases of MCAD deficiency. Our patient shows 
the mutation in both alleles. The question 
arises as to which factor(s) determine this 
clinical heterogeneity. It has been shown that 
the 985 point mutation results in a diminished 
concentration of MCAD protein as a conse­
quence of an enhanced degradation rate of the 
protein.2930 Recently, other point mutations, 
some of them being localised on exon 11 like 
the 985 mutation, have been found especially 
in compound heterozygotes.3037 40"42 Possibly 
environmental factors or the relative activity 
of the other enzymes of ^ -oxidation play a 
part in determining the phenotype in patients 
deficient in MCAD. It is important to realise 
that in adults with unexplained rhabdomyolysis 
and acute encephalopathy a diagnosis of 
MCAD deficiency, or other disturbances in 
fatty acid oxidation, should be considered.
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